| Literature DB >> 35698116 |
Camila M Clemente1, Sara M Robledo2, Soledad Ravetti3.
Abstract
INTRODUCTION: Despite the number of deaths and the significant economic and social costs associated with Chagas, Leishmaniasis and Malaria diseases worldwide, available drugs are limited and have serious side effects and high toxicity for the patient. Therefore, there is an urgent need for safe, low-cost, and effective treatments. Natural products are an important source of bioactive compounds and there is current interest in finding natural bioactive molecules that can be used for treating these parasitic diseases. In the present study we proposed to evaluate the in vitro antiparasitic activity of new menthol derivatives against Trypanosoma cruzi, Leishmania braziliensis and Plasmodium falciparum; moreover, we propose to explore their mode of action through in silico approaches.Entities:
Keywords: Antiparasitic; Cytotoxicity; Menthol; Molecular dynamics; Prodrugs
Mesh:
Substances:
Year: 2022 PMID: 35698116 PMCID: PMC9190099 DOI: 10.1186/s12906-022-03636-8
Source DB: PubMed Journal: BMC Complement Med Ther ISSN: 2662-7671
Fig. 1Synthesis general of menthol carbonates (1–9). Reagents and conditions: a CH2Cl2, N2, 25 °C, stirring, 1 h
In vitro cytotoxicity and antiprotozoal activity of menthol and its prodrugs
| Compound | Cytotoxicity | Antiplasmodial activity | Trypanocidal activity | Leishmanicidal activity | |||
|---|---|---|---|---|---|---|---|
| Menthol | 265.7 ± 188.1 | 358.5 ± 51.0 | 0.7 | 173.4 ± 28.9 | 1.5 | > 128.0 | > 2.1 |
| 68.5 ± 6.7 | 127.4 ± 9.9 | 0.5 | 105.45 ± 34.52 | 0.6 | 22.9 ± 2.8 | 3.0 | |
| 103.3 ± 35.8 | 28.4 ± 0.4 | 3.6 | 33.8 ± 4.3 | 3.1 | 28.4 ± 0.4 | 3.6 | |
| 57.0 ± 14.4 | 60.7 ± 1.2 | 0.9 | 33,83 ± 2,84 | 1.7 | 31.8 ± 4.1 | 1.8 | |
| 145.2 ± 74.5 | 60.7 ± 1.0 | 2.4 | 2061.7 ± 175.4 | 0.1 | 43.2 ± 0.3 | 3.4 | |
| 207.3 ± 38.2 | 56.3 ± 1.0 | 3.7 | 121.7 ± 21.4 | 1.7 | 59.3 ± 1.4 | 3.5 | |
| 221,51 ± 21,07 | 59.1 ± 2.6 | 3,7 | 29.6 ± 1.2 | 7.4 | 96.7 ± 0.6 | 2,3 | |
| 73.3 ± 15.8 | 432.5 ± 238.7 | 0.2 | 46.3 ± 4.9 | 1.6 | 28.2 ± 1.1 | 2.6 | |
| 48.4 ± 6.1 | 67.4 ± 5.8 | 0.7 | 27.6 ± 4.4 | 1.8 | > 23.5 | > 2.1 | |
| 44.1 ± 3.8 | 62.4 ± 6.5 | 0.7 | 26.7 ± 4.6 | 1.7 | 463.3 ± 205.7 | 0.1 | |
| DOXOd | 1.7 ± 0.2 | NAe | NA | NA | NA | NA | NA |
| CQf | 485.3 ± 16.3 | 10.5 ± 1.3 | 46.2 | NA | NA | NA | NA |
| BNZg | > 768.5 | NA | NA | 60.1 ± 12.2 | 12.8 | NA | NA |
| AMBh | 53.9 ± 7.4 | NA | NA | NA | NA | 0.4 ± 0.1 | 134.8 |
Data represent the lethal and effective concentration for each compound
aMedian lethal concentration
bMedian effective concentration
cIS Index of Selectivity = LC50/EC50
dDOXO Doxorubicin
eNA No apply, CQ Cloroquine, BNZ Benznidazole, AMB Amphotericin B
ADME molecular descriptors of compounds designed
| Compound | MW (g/mol) | LogP | HBA | HBD | TPSA(Å2) | RB | MR | RL | GR | VR | Synth. Acce |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Menthol | 156.27 | 2.58 | 1 | 1 | 20.23 | 1 | 49.23 | Yes | Yes | Yes | 2.63 |
| 1 | 214.31 | 3.04 | 3 | 0 | 35.54 | 4 | 60.44 | Yes | Yes | Yes | 3.49 |
| 2 | 228.33 | 3.33 | 3 | 0 | 35.54 | 5 | 65.25 | Yes | Yes | Yes | 3.64 |
| 3 | 242.36 | 3.74 | 3 | 0 | 35.54 | 6 | 70.06 | Yes | Yes | Yes | 3.75 |
| 4 | 242.36 | 3.64 | 3 | 0 | 35.54 | 5 | 70.06 | Yes | Yes | Yes | 3.75 |
| 5 | 256.39 | 3.98 | 3 | 0 | 35.54 | 7 | 74.86 | Yes | Yes | Yes | 3.86 |
| 6 | 270.41 | 4.42 | 3 | 0 | 35.54 | 8 | 79.67 | Yes | Yes | Yes | 3.97 |
| 7 | 284.44 | 4.68 | 3 | 0 | 35.54 | 9 | 84.48 | Yes | Yes | Yes | 4.08 |
| 8 | 298.47 | 5.15 | 3 | 0 | 35.54 | 10 | 89.28 | Yes | Yes | Yes | 4.20 |
| 9 | 312.49 | 5.39 | 3 | 0 | 35.54 | 11 | 94.09 | Yes | Yes | No | 4.31 |
MW Molecular weight, LogP octanol/water partition coefficient, HBA Hydrogen Bond Acceptor, HBD Hydrogen Bond Donor, TPSA Topological Polar Surface Area, RB: Rotatable Bond, and MR Molar Refractivity. LR Lipinski Rules, GR Ghose Rules, VR Veber Rules, and Synth. Acce. Synthetic accessibility
Fig. 2Predicted binding modes of menthol and natural substrate in complex with (A) TcDHODH, (B) LbDHODH and (C) PfDHODH
Fig. 3RMSD of the backbone atoms of the docked complexes. In red menthol complexes and in black natural substrate complexes
Predicted binding free energies (kcal/mol−1) and individual energy terms, calculated from molecular dynamics simulation through the MM/PBSA protocol for TcDHODH, LbDHODH and PfDHODH complexes
| Ligand | Energy Component (kcal/mol−1) | ||||
|---|---|---|---|---|---|
| (S)-dihydroorotate | -17.41 ± 2.00 | -17.18 ± 3.94 | -34.60 ± 4.46 | 25.42 ± 4.22 | -9.17 ± 3.44 |
| Menthol | -22.33 ± 1.44 | -4.65 ± 3.45 | -26.99 ± 2.54 | 16.37 ± 3.42 | -10.62 ± 3.63 |
| (S)-dihydroorotate | -20.44 ± 1.98 | -27.20 ± 3.18 | -47.65 ± 3.05 | 33.76 ± 2.21 | -13.88 ± 0.34 |
| Menthol | -26.22 ± 1.23 | -1.45 ± 0.73 | -27.68 ± 1.49 | 19.19 ± 276 | -8.48 ± 2.62 |
| (S)-dihydroorotate | -18.63 ± 2.98 | -60.50 ± 5.21 | -79.14 ± 4.00 | 50.44 ± 2.69 | -28.69 ± 3.65 |
| Menthol | -26.58 ± 1.83 | -13.65 ± 1.54 | -40.23 ± 1.85 | 19.13 ± 1.74 | -21.10 ± 2.06 |
ΔEvdw Van der Waals energy, Δele Electrostatic energy, ΔGgas Gas-phase free energy, Δgsol Solvation free energy., Δgtotal Total binding free energy